Curaleaf Asks Alberta Regulator to Halt Aurora's ATM, Citing 10.8% Dilution and $11M Higher Offer Cost
CURLF sits 87% above its 52-week low of $5.4.
Summary
Curaleaf filed an application with the Alberta Securities Commission to halt Aurora's ATM share issuance during its pending US$4.00 hostile offer, alleging the program has diluted Aurora shareholders by ~10.8% and increased the offer's cost by over US$11 million.
Key Events · M&A and Partnerships · CURLF
-
Regulator Application Filed
Curaleaf asked the Alberta Securities Commission to immediately halt Aurora's ATM share issuance while the US$4.00 hostile offer remains outstanding, requesting an expedited hearing.
-
Dilution Quantified
Aurora issued ~2.81M shares at an average US$3.04 since Curaleaf first expressed interest, diluting shareholders ~4.9% in that period and ~10.8% since the ATM program began in February 2026.
-
Offer Cost Increased
The ATM issuances have raised the aggregate value required to complete Curaleaf's offer by more than US$11 million.
-
Defensive Tactic Allegation
Curaleaf argues Aurora's ATM use is an improper and abusive defensive tactic, inconsistent with Aurora's stated 'debt-free' balance sheet and ~C$149 million cash position.
Analysis · CURLF · Life Sciences
Curaleaf escalated its hostile bid for Aurora Cannabis by formally asking the Alberta Securities Commission to cease-trade Aurora's at-the-market program while the US$4.00 offer remains open. The filing quantifies the damage: Aurora has issued roughly 2.81 million shares at an average US$3.04 since Curaleaf first expressed interest, diluting shareholders by about 4.9% in that window and 10.8% since the ATM launched in February 2026. Those issuances have raised the total cost of Curaleaf's offer by more than US$11 million. This is a direct regulatory attack on Aurora's defensive tactics and raises the stakes in an already contentious takeover battle.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $10.11 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.